These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 87747)

  • 21. Indication of an antipsychotic action of the opiate antagonist naloxone.
    Emrich HM; Cording C; Pirée S; Kölling A; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):265-70. PubMed ID: 30101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naloxone in the treatment of schizophrenia.
    Wen HL; Lo CW; Ho WK; Mehal ZD; Ng YH; Lam S; Ma L
    Mod Med Asia; 1978 Dec; 14(12):51-5. PubMed ID: 750907
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of naloxone on pentazocine induced hallucinations.
    Jago RH; Restall J; Stonham J
    J R Army Med Corps; 1984 Feb; 130(1):64-5. PubMed ID: 6716360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients.
    Naber D; Leibl K
    Pharmacopsychiatria; 1983 Mar; 16(2):43-5. PubMed ID: 6346348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxone in schizophrenia.
    Pickar D
    Lancet; 1983 Apr; 1(8328):819. PubMed ID: 6132151
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of naloxone on brain and behavior of a self-injurious woman.
    Sandman CA; Barron JL; Crinella FM; Donnelly JF
    Biol Psychiatry; 1987 Jul; 22(7):899-906. PubMed ID: 3607117
    [No Abstract]   [Full Text] [Related]  

  • 27. Application of the morphine antagonist naloxone in psychic disorders.
    Schenk GK; Enders P; Engelmeier MP; Ewert T; Herdemerten S; Köhler KH; Lodemann E; Matz D; Pach J
    Arzneimittelforschung; 1978; 28(8):1274-7. PubMed ID: 380575
    [No Abstract]   [Full Text] [Related]  

  • 28. Decreased polydipsia in schizophrenic patients treated with naloxone.
    Nishikawa T; Tsuda A; Tanaka M; Nishikawa M; Koga I; Uchida Y
    Am J Psychiatry; 1994 Jun; 151(6):947. PubMed ID: 8185016
    [No Abstract]   [Full Text] [Related]  

  • 29. Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients. An open trial.
    Jibiki I; Yamaguchi N; Momonoi F
    Eur J Clin Pharmacol; 1994; 46(4):367-9. PubMed ID: 7957524
    [No Abstract]   [Full Text] [Related]  

  • 30. [Various aspects of the interaction between the dopamine and opiate systems in schizophrenia].
    Anokhina IP
    Vestn Akad Med Nauk SSSR; 1982; (1):37-40. PubMed ID: 7064531
    [No Abstract]   [Full Text] [Related]  

  • 31. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects.
    Lehmann H; Nair NP; Kline NS
    Am J Psychiatry; 1979 Jun; 136(6):762-6. PubMed ID: 220889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Auditory hallucinations suppressed by etizolam in a patient with schizophrenia.
    Benazzi F; Mazzoli M; Rossi E
    Can J Psychiatry; 1993 Oct; 38(8):574-5. PubMed ID: 7902201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The possibility of endorphins playing a role in psychic disturbances].
    Emrich HM
    Arzneimittelforschung; 1978; 28(8):1270-3. PubMed ID: 223579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic pathomorphology during the terminal stages of schizophrenia].
    Vartanian FE
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 68(2):250-7. PubMed ID: 5661308
    [No Abstract]   [Full Text] [Related]  

  • 35. Lorazepam as an adjunct in the treatment of auditory hallucinations in a schizophrenic patient.
    Yassa R; Nastase C; Belzile L
    J Clin Psychopharmacol; 1989 Oct; 9(5):386. PubMed ID: 2794102
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of monoamine oxidase inhibitors in schizophrenia.
    Brenner R; Shopsin B
    Biol Psychiatry; 1980 Aug; 15(4):633-47. PubMed ID: 7397294
    [No Abstract]   [Full Text] [Related]  

  • 37. Behavioral and neuroendocrine effects of opioid receptor agonists in psychopathologic states.
    Judd LL; Risch SC; Segal DS; Janowsky DS; Huey LY
    Psychiatr Clin North Am; 1983 Sep; 6(3):393-402. PubMed ID: 6359090
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthetic enkephalin analogue in treatment of schizophrenia.
    Jørgensen A; Fog R; Veilis B
    Lancet; 1979 Apr; 1(8122):935. PubMed ID: 86715
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pimozide. Delusions and hallucinations].
    Roger BM; Guilloux J; Saillant A
    Ann Med Psychol (Paris); 1972; 2(3):419-25. PubMed ID: 4648230
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinico-pharmacological studies of sulpiride.
    Nishiura M
    Curr Ther Res Clin Exp; 1976 Aug; 20(2):164-72. PubMed ID: 821717
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.